Major Results About The Real Effect Of Liraglutide On Reducing Cardiovascular Risk Predictors: Systematic Review Of Clinical Utility
International Journal of Development Research
Major Results About The Real Effect Of Liraglutide On Reducing Cardiovascular Risk Predictors: Systematic Review Of Clinical Utility
Received 11th May, 2019; Received in revised form 06th June, 2019; Accepted 03rd July, 2019; Published online 28th August, 2019
Copyright © 2019, Alfredo Pinheiro Neto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction: Obesity portrays a multifactorial disease and presents a serious public health problem, with an alarming epidemic character. There are about two billion overweight and obese people in the world, and Brazil is in fifth place in the world ranking. This scenario is of concern as overweight promotes increased mortality related to the development of cardiorespiratory and metabolic diseases. Liraglutide (LG) is an analog of the hormone GLP-1. Incretins are hormones secreted through endocrine cells that are located in the small intestine epithelium and can control glycemic levels and decrease the weight to treat obesity. Objective: The aim of this study was to evaluate, through a systematic review, important clinical results on the real effect of Liraglutide in reducing the predictors of cardiovascular risk in patients with and without diabetes, as well as the assessment of patient survival. Methods: Following literary search criteria with the use of the MeSH Terms that were cited in the item on "Search strategies", a total of 68 clinical studies and reviews that were submitted for eligibility analysis were checked, and after that, 19 studies were selected, following the rules of systematic review-PRISMA. Major findings and Conclusion: LG is a GLP-1 receptor agonist that has been successfully used in the treatment of type 2 diabetes for several years. It was concluded that weight loss in obese non-diabetic patients was reasonable, with a high incidence of nausea in the treatment group. Weight loss is associated with an improvement in Quality of Life, and when compared by age and obesity. The underlying mechanism may be improved glycemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridemia in hyperglycemic patients. Therefore, clinical studies have shown that 12-month LG treatment in addition to ongoing hypoglycemic therapy significantly improves all major CVD risk factors and reduces cardiometabolic risk, as shown by visceral fat index values.
